### RAW SEQUENCE LISTING PATENT APPLICATION US/09/247,054

DATE: 01/05/2000 TIME: 08:47:49

Input Set: 1247054.RAW

This Raw Listing contains the General Information Section and up to first 5 pages.

```
<110> APPLICANT: Antoniou, Michael
                   Grosveld, Franklin G
         2
             <120> TITLE OF INVENTION: Self-Replicating Episomal Expression Vectors Conferring
         3
                   Tissue-Specific Gene Expression
         4
             <130> FILE REFERENCE: CACO0045
             <140> CURRENT APPLICATION NUMBER: US/09/247,054
         6
             <141> CURRENT FILING DATE: 1999-02-09
         7
             <150> EARLIER APPLICATION NUMBER: 08/914,715
         9
             <151> EARLIER FILING DATE: 1997-08-19
        10
             <150> EARLIER APPLICATION NUMBER: PCT/GB97/02213
            <151> EARLIER FILING DATE: 1997-08-18
        11
             <150> EARLIER APPLICATION NUMBER: 60/025,040
        13
             <151> EARLIER FILING DATE: 1996-08-28
        14
             <160> NUMBER OF SEQ ID NOS: 15
            <170> SOFTWARE: PatentIn Ver. 2.1
             <210> SEQ ID NO 1
        16
        17
             <211> LENGTH: 12
        18
            <212> TYPE: DNA
             <213> ORGANISM: Papillomavirus
        19
        20
             <400> SEQUENCE: 1
        21
                                                                                      12
                   accgttgccg gt
        22
             <210> SEQ ID NO 2
             <211> LENGTH:
        23
        24
            <212> TYPE:
        25
            <213> ORGANISM:
             <400> SEQUENCE: 2
        26
W-->
        27
                   This Sequence is intentionally skipped
             <210> SEQ ID NO 3
        28
        29
            <211> LENGTH: 31
             <212> TYPE: PRT
        30
        31
            <213> ORGANISM: Artificial Sequence
            <220> FEATURE:
             <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
        33
        34
             <400> SEQUENCE: 3
        35
                   Thr Arg Arg Ala Trp Arg Arg Ala Lys Arg Arg Ala Ala Arg Arg Cys
        36
                                                         10
        37
                   Gly Val Ser Ala Arg Arg Ala Ala Arg Arg Ala Trp Arg Arg Glu
        38
                                20
                                                     25
                                                                         30
        39
            <210> SEQ ID NO 4
        40
             <211> LENGTH: 31
        41
            <212> TYPE: PRT
        42
            <213> ORGANISM: Artificial Sequence
        43
             <220> FEATURE:
            <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
```

45

<400> SEQUENCE: 4

### RAW SEQUENCE LISTING PATENT APPLICATION US/09/247,054

TIME: 08:47:49

DATE: 01/05/2000

```
Thr Lys Lys Ala Trp Lys Lys Ala Glu Lys Lys Ala Ala Lys Lys Cys
       46
                                                        10
       47
                                    5
                  Gly Val Ser Ala Lys Lys Ala Ala Lys Lys Ala Trp Lys Lys Ala
       48
                                                    25
       49
            <210> SEQ ID NO 5
       50
            <211> LENGTH: 12
       51
       52
            <212> TYPE: PRT
       53
            <213> ORGANISM: Artificial Sequence
       54
            <220> FEATURE:
            <221> NAME/KEY: UNSURE
       55
       56 <222> LOCATION: (3)
       57
            <223> OTHER INFORMATION: Xaa is Serine, Threonine or Proline
       58
            <220> FEATURE:
           <221> NAME/KEY: UNSURE
       59
       60 <222> LOCATION: (7)
            <223> OTHER INFORMATION: Xaa is Alanine or Valine
       61
       62
           <220> FEATURE:
       63 <221> NAME/KEY: UNSURE
            <222> LOCATION: (8)
       64
            <223> OTHER INFORMATION: Xaa is Alanine, Threonine, or Proline
       65
       66
            <220> FEATURE:
       67
            <221> NAME/KEY: UNSURE
       68
            <222> LOCATION: (9)
            <223> OTHER INFORMATION: Kaa is Lysine, Alanine, Threonine or Valine
       69
       70
           <220> FEATURE:
       71
            <221> NAME/KEY: UNSURE
       72
            <222> LOCATION: (12)
            <223> OTHER INFORMATION: Xaa is Alanine or Valine
       73
       74
            <220> FEATURE:
       75
            <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
       76
            <400> SEQUENCE: 5
       77
                  Lys Lys Xaa Pro Lys Lys Xaa Xaa Xaa Pro Ala Xaa
W-->
       78
                                    5
                    1
       79
            <210> SEQ ID NO 6
       80
            <211> LENGTH: 9
            <212> TYPE: PRT
       81
       82
            <213> ORGANISM: Artificial Sequence
       83
            <220> FEATURE:
       84
            <221> NAME/KEY: UNSURE
       85
            <222> LOCATION: (1)
            <223> OTHER INFORMATION: Xaa is Alanine or Valine
       86
       87
            <220> FEATURE:
            <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
       88
       89
            <400> SEQUENCE: 6
       90
                  Xaa Lys Ser Pro Ala Lys Ala Lys Ala
W-->
       91
       92
            <210> SEQ ID NO 7
       93
            <211> LENGTH: 12
            <212> TYPE: PRT
```

3

### RAW SEQUENCE LISTING PATENT APPLICATION US/09/247,054

DATE: 01/05/2000 TIME: 08:47:49

```
<213> ORGANISM: Artificial Sequence
       95
            <220> FEATURE:
       96
            <221> NAME/KEY: UNSURE
       97
       98
            <222> LOCATION: (1)
       99
            <223> OTHER INFORMATION: Xaa is Lysine or Arginine
            <220> FEATURE:
       100
            <221> NAME/KEY: UNSURE
       101
       102 <222> LOCATION: (2)
       103 <223> OTHER INFORMATION: Xaa is Alanine or Threonine
       104
            <220> FEATURE:
      105 <221> NAME/KEY: UNSURE
      106 <222> LOCATION: (10)
            <223> OTHER INFORMATION: Xaa is Proline, Alanine or Serine
       107
           <220> FEATURE:
       108
      109 <221> NAME/KEY: UNSURE
      110
            <222> LOCATION: (12)
      111 <223> OTHER INFORMATION: Xaa is Lysine, Threonine or Valine
       112 <220> FEATURE:
            <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
       113
      114
            <400> SEQUENCE: 7
      115
                  Xaa Xaa Val Lys Pro Lys Ala Ala Lys Xaa Lys Xaa
W-->
                                    5
                                                       10
      116
            <210> SEQ ID NO 8
       117
       118 <211> LENGTH: 11
       119 <212> TYPE: PRT
       120 <213> ORGANISM: Artificial Sequence
       121
           <220> FEATURE:
      122 <221> NAME/KEY: UNSURE
      123 <222> LOCATION: (1)
       124
            <223> OTHER INFORMATION: Xaa is preferably Lysine or Threonine
       125 <220> FEATURE:
      126 <221> NAME/KEY: UNSURE
            <222> LOCATION: (2)
       127
       128
            <223> OTHER INFORMATION: Xaa is preferably Glysine or Glutamine
       129 <220> FEATURE:
      130 <221> NAME/KEY: UNSURE
      131
            <222> LOCATION: (3)
            <223> OTHER INFORMATION: Xaa is preferably Glycine, but can also be
      132
                  Aspartate, Glutamate, or Serine
      133
            <220> FEATURE:
       134
            <221> NAME/KEY: UNSURE
      135
      136
            <222> LOCATION: (4)
            <223> OTHER INFORMATION: Xaa is preferably Glycine, but can also be Lysine,
       137
                  Valine, Glutamine, or Threonine
      138
            <220> FEATURE:
      139
      140
            <221> NAME/KEY: UNSURE
            <222> LOCATION: (5)
       141
           <223> OTHER INFORMATION: Kaa is preferably Lysine or Alanine
       142
      143 <220> FEATURE:
       144
            <221> NAME/KEY: UNSURE
```

W-->

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/247,054

**54** TIME: 08:47:49

DATE: 01/05/2000

```
145
      <222> LOCATION: (6)
      <223> OTHER INFORMATION: Xaa is preferably Alanine or Lysine
146
    <220> FEATURE:
147
148
      <221> NAME/KEY: UNSURE
149
      <222> LOCATION: (7)
150
      <223> OTHER INFORMATION: Xaa is preferably Arginine, but can also be Valine
151
     <220> FEATURE:
152
153
    <221> NAME/KEY: UNSURE
154
      <222> LOCATION: (8)
155
      <223> OTHER INFORMATION: Xaa is preferably Alanine, but can also be
            Threonine, Histidine, or Proline
157
      <220> FEATURE:
      <221> NAME/KEY: UNSURE
158
159
     <222> LOCATION: (9)
     <223> OTHER INFORMATION: Xaa is preferably Lysine, Arginine, or Glutamine
160
161
      <220> FEATURE:
162
    <221> NAME/KEY: UNSURE
163
      <222> LOCATION: (10)
      <223> OTHER INFORMATION: Xaa is Alanine or Arginine
164
165
     <220> FEATURE:
     <221> NAME/KEY: UNSURE
166
      <222> LOCATION: (11)
167
      <223> OTHER INFORMATION: Xaa is preferably Lysine or Glutamine
168
169
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
170
171
      <400> SEQUENCE: 8
172
            Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
173
                              5
                                                 10
      <210> SEQ ID NO 9
174
     <211> LENGTH: 11
175
      <212> TYPE: PRT
177
      <213> ORGANISM: Artificial Sequence
178
      <220> FEATURE:
179
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
180
      <400> SEQUENCE: 9
181
            Lys Gly Gly Lys Ala Arg Ala Lys Ala Lys
182
              1
                              5
      <210> SEQ ID NO 10
183
184
      <211> LENGTH: 8
185
     <212> TYPE: PRT
186
      <213> ORGANISM: Artificial Sequence
187
      <220> FEATURE:
188
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
189
      <400> SEQUENCE: 10
190
            Pro Lys Lys Lys Arg Lys Val Gln
191
192
     <210> SEQ ID NO 11
     <211> LENGTH: 61
193
194
      <212> TYPE: PRT
```

5

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/247,054

Toward Cab TOATOEA DAW

DATE: 01/05/2000

TIME: 08:47:49

```
<213> ORGANISM: Artificial Sequence
195
196
     <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
197
198
      <400> SEQUENCE: 11
            Pro Lys Lys Arg Lys Val Glu Lys Lys Ser Pro Lys Lys Ala Lys
199
200
201
            Lys Pro Ala Lys Ser Pro Ala Lys Ala Lys Ala Lys Ala Lys
202
                         20
                                             25
            Pro Lys Ala Ala Lys Pro Lys Lys Pro Lys Lys Lys Arg Lys Val Glu
203
204
            Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala Cys
205
206
207
     <210> SEQ ID NO 12
208
     <211> LENGTH: 33
     <212> TYPE: PRT
209
210
     <213> ORGANISM: Artificial Sequence
211
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
212
     <400> SEQUENCE: 12
213
            Lys Ala Val Lys Pro Lys Ala Ala Lys Pro Lys Lys Pro Lys Lys
214
215
                              5
            Arg Lys Val Glu Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala
216
                                             25
217
                         20
218
            Cys
219
     <210> SEQ ID NO 13
     <211> LENGTH: 25
220
221
     <212> TYPE: PRT
     <213> ORGANISM: Artificial Sequence
222
223
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
224
225
     <400> SEQUENCE: 13
            Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala Lys Lys Ser Pro
226
227
228
            Lys Lys Ala Lys Lys Pro Ala Ala Cys
229
                         20
     <210> SEQ ID NO 14
230
231
     <211> LENGTH: 37
     <212> TYPE: PRT
232
     <213> ORGANISM: Artificial Sequence
233
234
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
235
236
      <400> SEQUENCE: 14
            Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala Lys Lys Ser Pro
237
238
            Lys Lys Ala Lys Lys Pro Ala Ala Lys Lys Ser Pro Lys Lys Ala Lys
239
240
                         20
                                             25
            Lys Pro Ala Ala Cys
241
242
                     35
243
      <210> SEQ ID NO 15
244
      <211> LENGTH: 61
```

6

## VERIFICATION SUMMARY PATENT APPLICATION US/09/247,054

DATE: 01/05/2000 TIME: 08:47:49

Line	?	Error/Warning		Original Text		
	-					
27	W	Line data has been	corrected			
77	W	"N" or "Xaa" used	Feature required	Lys Lys Xaa Pro Lys Lys Xaa Xaa Xaa Pro A		
90	W	"N" or "Xaa" used	Feature required	Xaa Lys Ser Pro Ala Lys Ala Lys Ala		
115	W	"N" or "Xaa" used	Feature required	Xaa Xaa Val Lys Pro Lys Ala Ala Lys Xaa L		
172	W	"N" or "Xaa" used	Feature required	Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa X		

## CORRECTION SUMMARY PATENT APPLICATION US/09/247,054

DATE: 01/05/2000 TIME: 08:47:49

Input Set: I247054.RAW

Line Original Text Corrected Data

27 This Sequence is intentionally skipped

1632

PAGE: 1

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/247,054

DATE: 01/04/2000

TIME: 12:43:38

Input Set: I247054.RAW

This Raw Listing contains the General Information
Section and up to first 5 pages.

Does Not Comply

Corrected Diskette Needed

```
<110> APPLICANT: Antoniou, Michael
 1
 2
          Grosveld, Franklin G
     <120> TITLE OF INVENTION: Self-Replicating Episomal Expression Vectors Conferring
 3
          Tissue-Specific Gene Expression
 4
     <130> FILE REFERENCE: CACO0045
     <140> CURRENT APPLICATION NUMBER: US/09/247,054
 6
 7
     <141> CURRENT FILING DATE: 1999-02-09
    <150> EARLIER APPLICATION NUMBER: 08/914,715
 8
    <151> EARLIER FILING DATE: 1997-08-19
 9
     <150> EARLIER APPLICATION NUMBER: PCT/GB97/02213
10
11
    <151> EARLIER FILING DATE: 1997-08-18
     <150> EARLIER APPLICATION NUMBER: 60/025,040
12
     <151> EARLIER FILING DATE: 1996-08-28
13
     <160> NUMBER OF SEQ ID NOS: 15
14
     <170> SOFTWARE: PatentIn Ver. 2.1
15
16
     <210> SEQ ID NO 1
17
     <211> LENGTH: 12
18
    <212> TYPE: DNA
     <213> ORGANISM: Papillomavirus
19
20
     <400> SEQUENCE: 1
          accgttgccg gt
                                                                               12
21
     <210> SEQ ID NO 2
22
    <211> LENGTH:
23
     <212> TYPE:
24
25
    <213> ORGANISM:
     <400> SEQUENCE: 2
27
          This Sequence is intentionally skipped
28
     <210> SEQ ID NO 3
29
     <211> LENGTH: 31
    <212> TYPE: PRT
30
31
    <213> ORGANISM: Artificial Sequence
32
    <220> FEATURE:
    <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
33
34
     <400> SEQUENCE: 3
           Thr Arg Arg Ala Trp Arg Arg Ala Lys Arg Arg Ala Ala Arg Arg Cys
35
36
          Gly Val Ser Ala Arg Arg Ala Ala Arg Arg Ala Trp Arg Arg Glu
37
38
                        20
                                            25
39
     <210> SEQ ID NO 4
40
     <211> LENGTH: 31
41
     <212> TYPE: PRT
     <213> ORGANISM: Artificial Sequence
42
43
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
44
```

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/247,054

Input Set: I247054.RAW

DATE: 01/04/2000

TIME: 12:43:38

```
<400> SEQUENCE: 4
                  Thr Lys Lys Ala Trp Lys Lys Ala Glu Lys Lys Ala Ala Lys Lys Cys
       46
       47
                  Gly Val Ser Ala Lys Lys Ala Ala Lys Lys Ala Trp Lys Lys Ala
       48
       49
            <210> SEQ ID NO 5
            <211> LENGTH: 12
       51
            <212> TYPE: PRT
            <213> ORGANISM: Artificial Sequence
       53
            <220> FEATURE:
            <221> NAME/KEY: UNSURE
       56
           <222> LOCATION: (3)
            <223> OTHER INFORMATION: Xaa is Serine, Threonine or Proline
       58
            <220> FEATURE:
       59
           <221> NAME/KĖY: UNSURE
            <222> LOCATION: (7)
            <223> OTHER INFORMATION: Xaa is Alanine or Valine
       61
            <220> FEATURE:
       63
            <221> NAME/KEY: UNSURE
            <222> LOCATION: (8)
            <223> OTHER INFORMATION: Xaa is Alanine, Threonine, or Proline
           <220> FEATURE:
       66
       67
            <221> NAME/KEY: UNSURE
       68
            <222> LOCATION: (9)
            <223> OTHER INFORMATION: Xaa is Lysine, Alanine, Threonine or Valine
       69
       70 <220> FEATURE:
       71 <221> NAME/KEY: UNSURE
           <222> LOCATION: (12)
           <223> OTHER INFORMATION: Xaa is Alanine or Valine
           <220> FEATURE:
            <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
            <400> SEQUENCE: 5 / /
            Lys Lys Xaa Pro Lys Lys Xaa Xaa Xaa Pro Ala Xaa
                              5 10
       78
                  1
       79
           <210> SEQ ID NO 6
       80
            <211> LENGTH: 9
           <212> TYPE: PRT
            <213> ORGANISM: Artificial Sequence
       82
       83
            <220> FEATURE:
            <221> NAME/KEY: UNSURE
            <222> LOCATION: (1)
       85
            <223> OTHER INFORMATION: Xaa is Alanine or Valine
       86
       87
            <220> FEATURE:
            <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
W--> 0 89
            <400> SEQUENCE: 6
                  Xaa Lys Ser Pro Ala Lys Ala Lys Ala
       92
            <210> SEQ ID NO 7
       93
           <211> LENGTH: 12
       94
            <212> TYPE: PRT
```

#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/247,054

Input Set: 1247054.RAW

DATE: 01/04/2000

TIME: 12:43:38

```
<213> ORGANISM: Artificial Sequence
  96
      <220> FEATURE:
      <221> NAME/KEY: UNSURE
  97
      <222> LOCATION: (1)
      <223> OTHER INFORMATION: Xaa is Lysine or Arginine
  99
      <220> FEATURE:
 100
      <221> NAME/KEY: UNSURE
 101
 102
      <222> LOCATION: (2)
      <223> OTHER INFORMATION: Xaa is Alanine or Threonine
 103
 104
      <220> FEATURE:
      <221> NAME/KEY: UNSURE
 106
      <222> LOCATION: (10)
 107
      <223> OTHER INFORMATION: Xaa is Proline, Alanine or Serine
      <220> FEATURE:
 108
 109
      <221> NAME/KEY: UNSURE
 110
      <222> LOCATION: (12)
      <223> OTHER INFORMATION: Xaa is Lysine, Threonine or Valine
 111
      <220> FEATURE:
 112
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
 113
      <400> SEQUENCE: 7
 114
            Xaa Xaa Val Lys Pro Lys Ala Ala Lys Xaa Lys Xaa
 115
 116
      <210> SEQ ID NO 8
 117
     <211> LENGTH: 11
 118
      <212> TYPE: PRT
119
 120
      <213> ORGANISM: Artificial Sequence
 121
      <220> FEATURE:
      <221> NAME/KEY: UNSURE
 122
 123
      <222> LOCATION: (1)
      <223> OTHER INFORMATION: Xaa is preferably Lysine or Threonine
124
 125
      <220> FEATURE:
      <221> NAME/KEY: UNSURE
 127
      <222> LOCATION: (2)
      <223> OTHER INFORMATION: Xaa is preferably Glysine or Glutamine
 128
 129 <220> FEATURE:
130 <221> NAME/KEY: UNSURE
 131
      <222> LOCATION: (3)
      <223> OTHER INFORMATION: Xaa is preferably Glycine, but can also be
132
            Aspartate, Glutamate, or Serine
134
      <220> FEATURE:
                                                        <
      <221> NAME/KEY: UNSURE
 135
136
      <222> LOCATION: (4)
      <223> OTHER INFORMATION: Xaa is preferably Glycine, but can also be Lysine,
137
 138
            Valine, Glutamine, or Threonine
      <220> FEATURE:
139
140 <221> NAME/KEY: UNSURE
141
      <222> LOCATION: (5)
      <223> OTHER INFORMATION: Xaa is preferably Lysine or Alanine
142
 143
      <220> FEATURE:
 144
      <221> NAME/KEY: UNSURE
```



#### RAW SEQUENCE LISTING

PATENT APPLICATION US/09/247,054

Input Set: 1247054.RAW

DATE: 01/04/2000

TIME: 12:43:38

```
<222> LOCATION: (6)
145
          <223> OTHER INFORMATION: Xaa is preferably Alanine or Lysine
146
          <220> FEATURE:
147
          <221> NAME/KEY: UNSURE
148
149
           <222> LOCATION: (7)
           <223> OTHER INFORMATION: Xaa is preferably Arginine, but can also be Valine
150
151
           <220> FEATURE:
152
          <221> NAME/KEY: UNSURE
153
          <222> LOCATION: (8)
           <223> OTHER INFORMATION: Xaa is preferably Alanine, but can also be
155
                      Threonine, Histidine, or Proline
156
           <220> FEATURE:
157
          <221> NAME/KEY: UNSURE
158
159
           <222> LOCATION: (9)
          <223> OTHER INFORMATION: Xaa is preferably Lysine, Arginine, or Glutamine
160
           <220> FEATURE:
161
           <221> NAME/KEY: UNSURE
162
          CONTRACTION: (10)
CONTRACTION: (10)<
163
165
           <221> NAME/KEY: UNSURE
166
           <222> LOCATION: (11)
167
           <223> OTHER INFORMATION: Xaa is preferably Lysine or Glutamine
168
169
           <220> FEATURE:
           <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
170
           <400> SEQUENCE: 8 /
171
                      172
                                                        5
                                                                                           10
173
           <210> SEQ ID NO 9
174
175
           <211> LENGTH: 11
           <212> TYPE: PRT
176
           <213> ORGANISM: Artificial Sequence
177
           <220> FEATURE:
178
           <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
179
           <400> SEQUENCE: 9
180
                      Lys Gly Gly Lys Ala Arg Ala Lys Ala Lys
181
                        1
                                                        5
                                                                                           10
182
           <210> SEQ ID NO 10
183
           <211> LENGTH: 8
184
185
           <212> TYPE: PRT
           <213> ORGANISM: Artificial Sequence
186
           <220> FEATURE:
187
           <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
188
           <400> SEQUENCE: 10
189
                      Pro Lys Lys Lys Arg Lys Val Gln
190
                          1
191
           <210> SEQ ID NO 11
192
193
           <211> LENGTH: 61
194
           <212> TYPE: PRT
```

PAGE: 5 RAW SEQUENCE LISTING DATE: 01/04/2000

` . · · · .

PATENT APPLICATION US/09/247,054 TIME: 12:43:38

```
195
      <213> ORGANISM: Artificial Sequence
196
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
197
198
      <400> SEQUENCE: 11
            Pro Lys Lys Arg Lys Val Glu Lys Lys Ser Pro Lys Lys Ala Lys
199
200
            Lys Pro Ala Ala Lys Ser Pro Ala Lys Ala Lys Ala Lys Ala Val Lys
201
                         20
                                             25
202
            Pro Lys Ala Ala Lys Pro Lys Lys Pro Lys Lys Arg Lys Val Glu
203
204
                                         40
205
            Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala Cys
206
                 50
      <210> SEQ ID NO 12
207
      <211> LENGTH: 33
208
      <212> TYPE: PRT
209
      <213> ORGANISM: Artificial Sequence
210
211
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
212
      <400> SEQUENCE: 12
            Lys Ala Val Lys Pro Lys Ala Ala Lys Pro Lys Lys Pro Lys Lys
214
            Arg Lys Val Glu Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala
216
217
218
            Cys
219
      <210> SEQ ID NO 13
220
      <211> LENGTH: 25
      <212> TYPE: PRT
221
      <213> ORGANISM: Artificial Sequence
223
      <220> FEATURE:
224
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
225
      <400> SEQUENCE: 13
            Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala Lys Lys Ser Pro
226
227
                              5
228
            Lys Lys Ala Lys Lys Pro Ala Ala Cys
229
230
      <210> SEQ ID NO 14
231
      <211> LENGTH: 37
232
      <212> TYPE: PRT
233
      <213> ORGANISM: Artificial Sequence
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: Peptide
235
      <400> SEQUENCE: 14
            Lys Lys Ser Pro Lys Lys Ala Lys Lys Pro Ala Ala Lys Lys Ser Pro
237
238
            Lys Lys Ala Lys Lys Pro Ala Ala Lys Lys Ser Pro Lys Lys Ala Lys
239
240
                         20
                                             25
241
            Lys Pro Ala Ala Cys
242
                     35
    <210> SEQ ID NO 15
243
244
      <211> LENGTH: 61
```

PAGE: 6.

# VERIFICATION SUMMARYDATE: 01/04/2000PATENT APPLICATION US/09/247,054TIME: 12:43:38

Line	?	Error/Warning	Original Text	Original Text			
27	W	Line data has been corrected					
77	W	"N" or "Xaa" used: Feature red	equired Lys Lys Xaa Pro Lys Lys Xaa Xaa Xaa Pro A				
90	W	"N" or "Xaa" used: Feature red	equired Xaa Lys Ser Pro Ala Lys Ala Lys Ala				
115	W	"N" or "Xaa" used: Feature red	equired Xaa Xaa Val Lys Pro Lys Ala Ala Lys Xaa L				
172	TAT	"N" or "Yaa" used. Feature red	emired Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa				

CORRECTION SUMMARY
PATENT APPLICATION US/09/247,054

DATE: 01/04/2000 TIME: 12:43:38

Input Set: I247054.RAW

Line Original Text Corrected Data

27

This Sequence is intentionally skipped